Trial Profile
Investigation of Pharmacokinetics, Safety, and Tolerability of BAY 94-8862 in Male and Female Subjects With Renal Impairment and in Age- and Weight-matched Healthy Subjects Following a Single Oral Dose of 10 mg BAY 94-8862 IR Tablet in a Single-center, Non-randomized, Non-controlled, Non-blinded, Observational Study With Group Stratification
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Finerenone (Primary)
- Indications Chronic heart failure; Diabetic nephropathies; Renal failure
- Focus Pharmacokinetics
- Sponsors Bayer
- 15 Dec 2016 New trial record
- 01 Nov 2016 Results published in the Clinical Pharmacology in Drug Development